SEARCH

SEARCH BY CITATION

References

  • 1
    American Cancer Society. Cancer Facts & Figures 2008. 2008 [cited 2008 Dec 4]; Available from: http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf.
  • 2
    Schnitt SJ, Connolly JL. Pathology of benign breast disorders. In: HarrisJR, LippmanME, MorrowM, OsborneCK, eds. Diseases of the Breast, 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2004. 7799.
  • 3
    Marshman E, Streuli CH. Insulin-like growth factors and insulin-like growth factor binding proteins in mammary gland function. Breast Cancer Res 2002; 4: 2319.
  • 4
    Sachdev D, Yee D. The IGF system and breast cancer. Endocr Relat Cancer 2001; 8: 197209.
  • 5
    Wood T, Yee D. Introduction: IGFs and IGFBPs in the normal mammary gland and in breast cancer. J Mammary Gland Biol Neoplasia 2000; 5: 15.
  • 6
    Kelley KM, Oh Y, Gargosky SE, Gucev Z, Matsumoto T, Hwa V, Ng L, Simpson DM, Rosenfeld RG. Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol 1996; 28: 61937.
  • 7
    Hadsell DL, Bonnette SG. IGF and insulin action in the mammary gland: lessons from transgenic and knockout models. J Mammary Gland Biol Neoplasia 2000; 5: 1930.
  • 8
    Laban C, Bustin SA, Jenkins PJ. The GH-IGF-I axis and breast cancer. Trends Endocrinol Metab 2003; 14: 2834.
  • 9
    Fletcher O, Gibson L, Johnson N, Altmann DR, Holly JM, Ashworth A, Peto J, Silva Idos S. Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review. Cancer Epidemiol Biomarkers Prev 2005; 14: 219.
  • 10
    Eliassen AH, Hankinson SE. Endogenous hormone levels and risk of breast, endometrial and ovarian cancers: prospective studies. Adv Exp Med Biol 2008; 630: 14865.
  • 11
    Al-Zahrani A, Sandhu MS, Luben RN, Thompson D, Baynes C, Pooley KA, Luccarini C, Munday H, Perkins B, Smith P, Pharoah PD, Wareham NJ, et al. IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. Hum Mol Genet 2006; 15: 110.
  • 12
    Canzian F, McKay JD, Cleveland RJ, Dossus L, Biessy C, Rinaldi S, Landi S, Boillot C, Monnier S, Chajes V, Clavel-Chapelon F, Tehard B, et al. Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study. Br J Cancer 2006; 94: 299307.
  • 13
    Cheng I, DeLellis Henderson K, Haiman CA, Kolonel LN, Henderson BE, Freedman ML, Le Marchand L. Genetic determinants of circulating insulin-like growth factor (IGF)-I. IGF binding protein (BP)-1, and IGFBP-3 levels in a multiethnic population. J Clin Endocrinol Metab 2007; 92: 36606.
  • 14
    Diorio C, Brisson J, Berube S, Pollak M. Genetic polymorphisms involved in insulin-like growth factor (IGF) pathway in relation to mammographic breast density and IGF levels. Cancer Epidemiol Biomarkers Prev 2008; 17: 8808.
  • 15
    Patel AV, Cheng I, Canzian F, Le Marchand L, Thun MJ, Berg CD, Buring J, Calle EE, Chanock S, Clavel-Chapelon F, Cox DG, Dorronsoro M, et al. IGF-1, IGFBP-1, and. IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS ONE. 2008; 3: e2578.
  • 16
    Ren Z, Cai Q, Shu XO, Cai H, Li C, Yu H, Gao YT, Zheng W. Genetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women. Cancer Epidemiol Biomarkers Prev 2004; 13: 12905.
  • 17
    Slattery ML, Baumgartner KB, Byers T, Guiliano A, Sweeney C, Herrick J, Curtin K, Murtaugh M, Wolff R. Genetic, anthropometric, and lifestyle factors associated with IGF-1 and IGFBP-3 levels in Hispanic and non-Hispanic white women. Cancer Causes Control 2005; 16: 114757.
  • 18
    Verheus M, McKay JD, Kaaks R, Canzian F, Biessy C, Johansson M, Grobbee DE, Peeters PH, van Gils CH. Common genetic variation in the IGF-1 gene, serum IGF-I levels and breast density. Breast Cancer Res Treat 2008; 112: 10922.
  • 19
    Wagner K, Hemminki K, Forsti A. The GH1/IGF-1 axis polymorphisms and their impact on breast cancer development. Breast Cancer Res Treat 2007; 104: 23348.
  • 20
    Cheng I, Penney KL, Stram DO, Le Marchand L, Giorgi E, Haiman CA, Kolonel LN, Pike M, Hirschhorn J, Henderson BE, Freedman ML. Haplotype-based association studies of IGFBP1 and IGFBP3 with prostate and breast cancer risk: the multiethnic cohort. Cancer. Epidemiol Biomarkers Prev 2006; 15: 19937.
  • 21
    Rohrbacher M, Risch A, Kropp S, Chang-Claude J. The A(-336C) insulin-like growth factor binding protein-3 promoter polymorphism is not a modulator of breast cancer risk in Caucasian women. Cancer Epidemiol Biomarkers Prev 2005; 14: 28990.
  • 22
    Setiawan VW, Cheng I, Stram DO, Penney KL, Le Marchand L, Altshuler D, Kolonel LN, Hirschhorn J, Henderson BE, Freedman ML. IGF-I genetic variation and breast cancer: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 2006; 15: 1724.
  • 23
    Slattery ML, Sweeney C, Wolff R, Herrick J, Baumgartner K, Giuliano A, Byers T. Genetic variation in IGF1. IGFBP3, IRS1, IRS2 and risk of breast cancer in women living in. Southwestern United States. Breast Cancer Res Treat 2007; 104: 197209.
  • 24
    Helle SI, Anker GB, Meadows K, Holly JM, Lonning PE. Alterations in the insulin-like growth factor system during the menstrual cycle in normal women. Maturitas 1998; 28: 25965.
  • 25
    Juul A, Scheike T, Pedersen AT, Main KM, Andersson AM, Pedersen LM, Skakkebaek NE. Changes in serum concentrations of growth hormone, insulin, insulin-like growth factor and insulin-like growth factor-binding proteins 1 and 3 and urinary growth hormone excretion during the menstrual cycle. Hum Reprod 1997; 12: 21238.
  • 26
    Missmer SA, Bertone-Johnson ER, Spiegelman D, Barbieri RL, Pollak M, Hankinson SE. Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2- to 3-year period. Cancer Epidemiol Biomarkers Prev 2006; 15: 9728.
  • 27
    Hunter DJ, Riboli E, Haiman CA, Albanes D, Altshuler D, Chanock SJ, Haynes RB, Henderson BE, Kaaks R, Stram DO, Thomas G, Thun MJ, et al. A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer 2005; 5: 97785.
  • 28
    Kolonel LN, Henderson BE, Hankin JH, Nomura AM, Wilkens LR, Pike MC, Stram DO, Monroe KR, Earle ME, Nagamine FS. A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol 2000; 151: 34657.
  • 29
    USC/Norris Comprehensive Cancer Center. Available from: http://www.uscnorris.com/MECGenetics/.
  • 30
    Cheng I, Stram DO, Penney KL, Pike M, Le Marchand L, Kolonel LN, Hirschhorn J, Altshuler D, Henderson BE, Freedman ML. Common genetic variation in IGF1 and prostate cancer risk in the Multiethnic Cohort. J Natl Cancer Inst 2006; 98: 12334.
  • 31
    Lewontin RC. The interaction of selection and linkage. II. Optimum models. Genetics 1964; 50: 75782.
  • 32
    Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, et al. The structure of haplotype blocks in the human genome. Science 2002; 296: 22259.
  • 33
    Stram DO, Haiman CA, Hirschhorn JN, Altshuler D, Kolonel LN, Henderson BE, Pike MC. Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study. Hum Hered 2003; 55: 2736.
  • 34
    Kraft P, Cox DG, Paynter RA, Hunter D, De Vivo I. Accounting for haplotype uncertainty in matched association studies: a comparison of simple and flexible techniques. Genet Epidemiol 2005; 28: 26172.
  • 35
    Zaykin DV, Westfall PH, Young SS, Karnoub MA, Wagner MJ, Ehm MG. Testing association of statistically inferred haplotypes with discrete and continuous traits in samples of unrelated individuals. Hum Hered 2002; 53: 7991.
  • 36
    Schernhammer ES, Holly JM, Hunter DJ, Pollak MN, Hankinson SE. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocr Relat Cancer 2006; 13: 58392.
  • 37
    Baglietto L, English DR, Hopper JL, Morris HA, Tilley WD, Giles GG. Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2007; 16: 7638.
  • 38
    Rinaldi S, Peeters PH, Berrino F, Dossus L, Biessy C, Olsen A, Tjonneland A, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Tehard B, Nagel G, et al. IGF-I. IGFBP-3 and breast cancer risk in women: the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 2006; 13: 593605.
  • 39
    Yu H, Jin F, Shu XO, Li BD, Dai Q, Cheng JR, et al. Insulin-like growth factors and breast cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev 2002;11:70512.
  • 40
    Burger AM, Leyland-Jones B, Banerjee K, Spyropoulos DD, Seth A. Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer. Eur J Cancer 2005; 41: 151527.
  • 41
    Subramanian A, Sharma A, Mokbel K. Insulin-like growth factor binding proteins and breast cancer. Breast Cancer Res Treat 2008; 107: 18194.
  • 42
    Chen JC, Shao ZM, Sheikh MS, Hussain A, LeRoith D, Roberts CTJ, Fontana JA. Insulin-like growth factor-binding protein enhancement of insulin-like growth factor-I (IGF-1)-mediated DNA synthesis and IGF-I binding in a human breast carcinoma cell line. J Cell Physiol 1994; 158: 6978.
  • 43
    McCaig C, Fowler CA, Laurence NJ, Lai T, Savage PB, Holly JM, Perks CM. Differential interactions between IGFBP-3 and transforming growth factor-beta (TGF-beta) in normal vs cancerous breast epithelial cells. Br J Cancer 2002; 86: 19639.
  • 44
    Perks CM, McCaig C, Clarke JB, Clemmons DR, Holly JM. A non-IGF binding mutant of IGFBP-3 modulates cell function in breast epithelial cells. Biochem Biophys Res Commun 2002; 294: 98894.
  • 45
    Martin JL, Weenink SM, Baxter RC. Insulin-like growth factor-binding protein-3 potentiates epidermal growth factor action in MCF-10A mammary epithelial cells. Involvement of p44/42 and p38 mitogen-activated protein kinases. J Biol Chem 2003; 278: 296976.
  • 46
    Butt AJ, Martin JL, Dickson KA, McDogall F, Firth SM, Baxter RC. Insulin-like growth factor binding protein-3 expression is associated with growth stimulation of T47D human breast cancer cells: the role of altered epidermal growth factor signaling. J Clin Endocrinol Metab 2004; 89: 19506.
  • 47
    Firth SM, Fanayan S, Benn D, Baxter RC. Development of resistance to insulin-like growth factor binding protein-3 in transfected T47D breast cancer cells. Biochem Biophys Res Commun 1998; 246: 3259.
  • 48
    Deal C, Ma J, Wilkin F, Paquette J, Rozen F, Ge B, Hudson T, Stampfer M, Pollak M. Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab 2001; 86: 127480.